YAQ007对比利福昔明在肝硬化患者中的2a期随机开放标签研究
本研究为探索性2a期随机开放标签多中心研究,纳入48例有显性肝性脑病病史的肝硬化患者,按1:1:1:1随机接受三种YAQ007口服方案或利福昔明治疗5天。结果显示YAQ007在≥4g每日两次剂量下具有短期降氨活性,尿苯乙酰谷氨酰胺排泄增加,安全性与利福昔明总体相似。
要点
- YAQ007在≥4g每日两次剂量下第5天氨水平较基线下降。
- 所有YAQ007剂量组第5天尿苯乙酰谷氨酰胺排泄较第1天增加。
- YAQ007组治疗中出现不良事件发生率为55.6%,以轻度胃肠和神经症状为主。
核心结论
- 口服YAQ007在≥4g每日两次剂量下显示出短期降氨活性。
- 研究为探索性设计,结果需进一步临床验证。
研究设计与样本
- 随机、开放标签、多中心2a期探索性研究。
- 纳入48例肝硬化且有显性肝性脑病病史患者,按1:1:1:1随机分组。
- YAQ007组接受2g每日三次、4g每日两次或4g每日三次,对照组接受利福昔明550mg每日两次,疗程5天,住院条件下进行。
主要发现
- 第5天氨水平下降见于YAQ007 4g每日两次组(p=0.002)和4g每日三次组(p=0.009)。
- 多变量校正后,治疗组B对比组D、胆红素、INR和钠是绝对氨降低的显著影响因素(p<0.05)。
- 所有YAQ007剂量组第5天尿苯乙酰谷氨酰胺排泄较第1天增加(p<0.001)。
- 暴露-反应关系变异,未显示明确的剂量-反应关系。
- YAQ007组20例(55.6%)和利福昔明组5例(41.7%)发生至少1例治疗中出现的不良事件,主要为轻度胃肠和神经症状。
临床怎么用
- YAQ007≥4g每日两次可能作为肝硬化伴显性肝性脑病病史患者短期降氨的候选方案,需进一步验证。
局限性
- 探索性设计,样本量小,结果仅具假设生成性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Ammonia is central in the pathogenesis of HE, but there are no approved treatments targeting ammonia. L -Ornithine Phenylacetate (YAQ007) is a novel drug that effectively reduces ammonia when administered intravenously. This exploratory phase 2a study evaluated the short-term pharmacodynamics, pharmacokinetics, and safety of oral YAQ007 in patients with cirrhosis and a history of overt HE. APPROACH AND RESULTS: In this randomized, open-label, multicenter study, 48 cirrhosis patients (28 male, mean of 57.2 y, Child-Pugh of 8, and MELD score of 10) were randomized (1:1:1:1) to 1 of 3 YAQ007 dosing regimens (2 g three times daily; 4 g twice daily; 4 g three times daily) or rifaximin (550 mg twice daily) for 5 days under inpatient conditions. A decrease of ammonia at day 5 was observed in group C ( p =0.009) and group B ( p =0.002). After multivariable adjustment, treatment group B versus group D, bilirubin, INR, and sodium ( p <0.05) remained significant factors for absolute ammonia reduction. Urinary phenylacetylglutamine excretion increased on day 5 compared with day 1 across all YAQ007 dose groups ( p <0.001). Exposure-response relationships were variable, and a clear dose-response relationship was not demonstrated. Overall, 20 (55.6%) patients who received YAQ007 and 5 (41.7%) who received rifaximin had at least 1 treatment-emergent adverse event, with mainly mild gastrointestinal and neurological symptoms. CONCLUSIONS: In this phase 2a study, oral YAQ007 demonstrated short-term ammonia-lowering activity at doses ≥4 g BID. Given the exploratory design, these findings are hypothesis-generating and support further clinical evaluation.
引用
- Ballester MP, Carbonell-Asins JA, Elshabrawi A, et al. A randomized, open-label, phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosis. Hepatology. 2026. PMID: 41931103. doi:10.1097/HEP.0000000000001748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。